Inactive Instrument

Press Releases Asterias Biotherapeutics Inc OTC Bulletin Board

Equities

US04624N1072

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	19-01-24	GL
Asterias Biotherapeutics Reports Third Quarter Results	18-11-09	GL
Asterias Biotherapeutics : BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company	18-11-08	BU
Asterias Biotherapeutics : BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update	18-11-08	BU
Asterias Biotherapeutics Announces Facilities and IP License Option Agreements	18-10-01	GL
FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program	18-09-20	GL
Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)	18-09-04	GL
Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference	18-08-29	GL
Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress	18-08-09	GL
Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	18-07-31	GL
Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018	18-07-26	GL
Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	18-07-17	GL
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke	18-07-12	GL
Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer	18-06-12	GL
Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury	18-06-05	GL
Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress	18-05-16	GL
Asterias Biotherapeutics to Report First Quarter 2018 Results on May 9, 2018	18-05-03	GL
Asterias Biotherapeutics to Present Safety and Efficacy Data from AST-OPC1 SCiStar Study at the American Spinal Injury Association (ASIA) 2018 Annual Meeting	18-05-02	GL
Asterias Biotherapeutics to Present AST-OPC1 Program Update at the Upcoming American Society for Neural Therapy and Repair Conference	18-04-27	GL
Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2	18-04-25	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Asterias Biotherapeutics Inc OTC Bulletin Board

Equities

US04624N1072

Press Releases

Filters